Diquet B, Garraffo R, Blanche S, Deville A, Etienne SD, Bidault R; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 195 (abstract no. S.B.438).
Pharmacologie Clinique, CHU PITIE-SALPETRIERE, France
OBJECTIVE: To study the pharmacokinetics of zidovudine and its glucuronide in children of various group of age, to characterize the influence of cotrimoxazole on zidovudine metabolism, and ensure a therapeutic drug monitoring. METHODS: 32 children divided in 3 groups have been studied: - 8 children, 0.4-12.5 years old, underwent an initial two weeks treatment with zidovudine as an 1 hour infusion at a dose of 100 mg/m2 every six hours. Then they were switched to an oral dose on the same schedule; the children received prophylactic cotrimoxazole (25 mg/Kg/day) from the day 3. Blood samples were drawn on day 3, 11 and 28. Urine samples were collected. - 3 new borns, 15-21 days old, received an 1 hour infusion (100 mg/m2) and were sampled at time 1-2-3-4 H to have an estimation of their PK parameters. - 21 children,0.33-15.6 years aged, received different oral doses (28-156mg/m2) the dosing regimen being established according to hematological status. All the samples were assayed by HPLC. RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: Some age-related differences in the overall elimination for zidovudine do exist and a relatively low rate of glucuronidation in children might explain these differences in younger children.
Publication Types:
Keywords:
- Administration, Oral
- Child
- Drug Administration Routes
- Humans
- Zidovudine
- metabolism
- methods
- pharmacokinetics
Other ID:
UI: 102196249
From Meeting Abstracts